Liquid chromatographic-mass spectrometric determination of haloperidol and its metabolites in human plasma and urine. 2002

Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
Department of Legal Medicine, Aichi Medical University School of Medicine, Nagakute-cho, Aichi 480-1195, Japan.

Haloperidol and its two metabolites, reduced haloperidol and 4-(4-chlorophenyl)-4-hydroxypiperidine (CPHP) in human plasma and urine were analyzed by HPLC-MS using a new polymer column (MSpak GF-310), which enabled direct injection of crude biological samples without pretreatment. Recoveries of haloperidol and reduced haloperidol spiked into plasma were 64.4-76.1% and 46.8-50.2%, respectively; those for urine were 87.3-99.4% and 94.2-98.5%, respectively; those of CPHP for both samples were not less than 92.7%. The regression equations for haloperidol, reduced haloperidol and CPHP showed good linearity in the ranges of 10-800, 15-800 and 400-800 ng/ml, respectively, for both plasma and urine. Their detection limits were 5, 10 and 300 ng/ml, respectively, for both samples. Thus, the present method was sensitive enough for detection and determination of high therapeutic and toxic levels for haloperidol and its metabolites present in biological samples.

UI MeSH Term Description Entries
D002851 Chromatography, High Pressure Liquid Liquid chromatographic techniques which feature high inlet pressures, high sensitivity, and high speed. Chromatography, High Performance Liquid,Chromatography, High Speed Liquid,Chromatography, Liquid, High Pressure,HPLC,High Performance Liquid Chromatography,High-Performance Liquid Chromatography,UPLC,Ultra Performance Liquid Chromatography,Chromatography, High-Performance Liquid,High-Performance Liquid Chromatographies,Liquid Chromatography, High-Performance
D006220 Haloperidol A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279) Haldol
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012680 Sensitivity and Specificity Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed) Specificity,Sensitivity,Specificity and Sensitivity
D013056 Spectrophotometry, Ultraviolet Determination of the spectra of ultraviolet absorption by specific molecules in gases or liquids, for example Cl2, SO2, NO2, CS2, ozone, mercury vapor, and various unsaturated compounds. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Ultraviolet Spectrophotometry
D013058 Mass Spectrometry An analytical method used in determining the identity of a chemical based on its mass using mass analyzers/mass spectrometers. Mass Spectroscopy,Spectrometry, Mass,Spectroscopy, Mass,Spectrum Analysis, Mass,Analysis, Mass Spectrum,Mass Spectrum Analysis,Analyses, Mass Spectrum,Mass Spectrum Analyses,Spectrum Analyses, Mass
D014150 Antipsychotic Agents Agents that control agitated psychotic behavior, alleviate acute psychotic states, reduce psychotic symptoms, and exert a quieting effect. They are used in SCHIZOPHRENIA; senile dementia; transient psychosis following surgery; or MYOCARDIAL INFARCTION; etc. These drugs are often referred to as neuroleptics alluding to the tendency to produce neurological side effects, but not all antipsychotics are likely to produce such effects. Many of these drugs may also be effective against nausea, emesis, and pruritus. Antipsychotic,Antipsychotic Agent,Antipsychotic Drug,Antipsychotic Medication,Major Tranquilizer,Neuroleptic,Neuroleptic Agent,Neuroleptic Drug,Neuroleptics,Tranquilizing Agents, Major,Antipsychotic Drugs,Antipsychotic Effect,Antipsychotic Effects,Antipsychotics,Major Tranquilizers,Neuroleptic Agents,Neuroleptic Drugs,Tranquillizing Agents, Major,Agent, Antipsychotic,Agent, Neuroleptic,Drug, Antipsychotic,Drug, Neuroleptic,Effect, Antipsychotic,Major Tranquilizing Agents,Major Tranquillizing Agents,Medication, Antipsychotic,Tranquilizer, Major
D015203 Reproducibility of Results The statistical reproducibility of measurements (often in a clinical context), including the testing of instrumentation or techniques to obtain reproducible results. The concept includes reproducibility of physiological measurements, which may be used to develop rules to assess probability or prognosis, or response to a stimulus; reproducibility of occurrence of a condition; and reproducibility of experimental results. Reliability and Validity,Reliability of Result,Reproducibility Of Result,Reproducibility of Finding,Validity of Result,Validity of Results,Face Validity,Reliability (Epidemiology),Reliability of Results,Reproducibility of Findings,Test-Retest Reliability,Validity (Epidemiology),Finding Reproducibilities,Finding Reproducibility,Of Result, Reproducibility,Of Results, Reproducibility,Reliabilities, Test-Retest,Reliability, Test-Retest,Result Reliabilities,Result Reliability,Result Validities,Result Validity,Result, Reproducibility Of,Results, Reproducibility Of,Test Retest Reliability,Validity and Reliability,Validity, Face

Related Publications

Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
September 2002, Journal of chromatography. A,
Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
August 2003, Journal of mass spectrometry : JMS,
Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
September 2011, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences,
Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
December 1989, Journal of chromatography,
Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
May 1984, Clinical chemistry,
Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
May 2005, Analytical and bioanalytical chemistry,
Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
November 2006, Biomedical chromatography : BMC,
Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
May 2007, Biomedical chromatography : BMC,
Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
December 1987, Arzneimittel-Forschung,
Tetsuya Arinobu, and Hideki Hattori, and Masae Iwai, and Akira Ishii, and Takeshi Kumazawa, and Osamu Suzuki, and Hiroshi Seno
September 1984, Journal of pharmaceutical sciences,
Copied contents to your clipboard!